Head and neck cancer Cancer Malignant neoplasm of other and ill-defined sites
Conditions
Interventions
Patients are randomised to one of two treatment regimens:
1. Group A: Cisplatinum repeated every 21 days for a maximum of six cycles
2. Group B: Cisplatinum plus nifedipine repeated every 21 days for
Sponsors
North West Cancer Research Fund (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with either advanced squamous cell carcinoma of the head and neck, not previously treated, or recurrent squamous cell carcinoma of the head and neck after previous radiotherapy or surgery 2. Measurable histologically confirmed, squamous cell carcinoma of the head and neck. The primary sites will be: 2.1. Mouth 2.2. Nasopharynx 2.3. Oropharynx 2.4. Hypopharynx 2.5. Larynx 2.6. Nose and sinuses 2.7. Middle ear 3. No prior chemotherapy 4. Not suitable for surgery or radiotherapy with a curative purpose 5. Karnofsky performance greater than 50 6. Minimum of three weeks since prior radiotherapy and or surgery and patients must have fully recovered from such prior treatments 7. Adequate bone marrow and renal function 8. No active infection 9. No concomitant or prior malignancy except adequately treated basal cell carcinoma of the skin and in situ carcinoma of the uterine cervix
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed